CLINICAL TRIALS PROFILE FOR PARNATE

All Clinical Trials for PARNATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00223691 ↗	Treatment of Orthostatic Hypotension in Autonomic Failure	Completed	Vanderbilt University	Phase 1	2002-03-01	The autonomic nervous system serves multiple regulatory functions in the body, including the regulation of blood pressure and heart rate, gut motility, sweating and sexual function. There are several diseases characterized by abnormal function of the autonomic nervous system. Medications can also alter autonomic function. Impairment of the autonomic nervous system by diseases or drugs may lead to several symptoms, including blood pressure problems (e.g., high blood pressure lying down and low blood pressure on standing), sweating abnormalities, constipation or diarrhea and sexual dysfunction. Because treatment options for these patients are limited. We propose to study patients autonomic failure and low blood pressure upon standing and determine the cause of their disease by history and examination and their response to autonomic testing which have already been standardized in our laboratory. Based on their possible cause, we will tests different medications that may alleviate their symptoms.
NCT00223691 ↗	Treatment of Orthostatic Hypotension in Autonomic Failure	Completed	Vanderbilt University Medical Center	Phase 1	2002-03-01	The autonomic nervous system serves multiple regulatory functions in the body, including the regulation of blood pressure and heart rate, gut motility, sweating and sexual function. There are several diseases characterized by abnormal function of the autonomic nervous system. Medications can also alter autonomic function. Impairment of the autonomic nervous system by diseases or drugs may lead to several symptoms, including blood pressure problems (e.g., high blood pressure lying down and low blood pressure on standing), sweating abnormalities, constipation or diarrhea and sexual dysfunction. Because treatment options for these patients are limited. We propose to study patients autonomic failure and low blood pressure upon standing and determine the cause of their disease by history and examination and their response to autonomic testing which have already been standardized in our laboratory. Based on their possible cause, we will tests different medications that may alleviate their symptoms.
NCT00296686 ↗	Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression	Terminated	New York State Psychiatric Institute	Phase 4	2001-09-01	This pilot study will assess the efficacy of several sequential pharmacological treatments for patients with Refractory Depression.
NCT00653393 ↗	Bioavailability Study of Tranylcypromine 10mg Tablets Under Fasting Conditions	Completed	SFBC Ft. Myers, Inc	Phase 1	2004-10-01	To compare the single-dose Bioavailability of Tranylcypromine and Parnate
NCT00653393 ↗	Bioavailability Study of Tranylcypromine 10mg Tablets Under Fasting Conditions	Completed	Par Pharmaceutical, Inc.	Phase 1	2004-10-01	To compare the single-dose Bioavailability of Tranylcypromine and Parnate
NCT01031810 ↗	PET Biomarkers in Treatment Resistant Depression	Terminated	National Institute of Mental Health (NIMH)	Phase 4	2009-11-01	The primary objectives of the study are to test whether brain Mono Amine Oxidase-A (MAO-A) levels are elevated in patients with treatment-resistant major depression, and to explore whether MAO-A brain levels predict treatment outcome with Mono Amine Oxidase Inhibitor (MAOI) medication in this population.
NCT01031810 ↗	PET Biomarkers in Treatment Resistant Depression	Terminated	New York State Psychiatric Institute	Phase 4	2009-11-01	The primary objectives of the study are to test whether brain Mono Amine Oxidase-A (MAO-A) levels are elevated in patients with treatment-resistant major depression, and to explore whether MAO-A brain levels predict treatment outcome with Mono Amine Oxidase Inhibitor (MAOI) medication in this population.

Clinical Trial Conditions for PARNATE

Condition Name

Condition Name for PARNATE
Intervention	Trials
Bipolar Disorder I or II	1
Major Depression	1
Major Depressive Disorder	1
Orthostatic Hypotension	1

Condition MeSH

Condition MeSH for PARNATE
Intervention	Trials
Depressive Disorder	4
Depression	4
Depressive Disorder, Major	3
Depressive Disorder, Treatment-Resistant	2

Clinical Trial Locations for PARNATE

Trials by Country

Trials by Country for PARNATE
Location	Trials
United States	6

Trials by US State

Trials by US State for PARNATE
Location	Trials
New York	3
Maryland	1
Florida	1
Tennessee	1

Clinical Trial Progress for PARNATE

Clinical Trial Phase

Clinical Trial Phase for PARNATE
Clinical Trial Phase	Trials
Phase 4	3
Phase 1	2
N/A	1

Clinical Trial Status

Clinical Trial Status for PARNATE
Clinical Trial Phase	Trials
Completed	3
Terminated	2
Withdrawn	1

Clinical Trial Sponsors for PARNATE

Sponsor Name

Sponsor Name for PARNATE
Sponsor	Trials
New York State Psychiatric Institute	3
Sheppard Pratt Health System	1
Vanderbilt University	1

Sponsor Type

Sponsor Type for PARNATE
Sponsor	Trials
Other	7
Industry	2
NIH	1

Last updated: April 27, 2026

Parnate (tranylcypromine): Clinical Trials Update, Market Analysis, and 2025-2035 Projection

What is Parnate and what parts of the pipeline matter now?

Parnate is the brand name for tranylcypromine, an oral monoamine oxidase inhibitor (MAOI). Commercial and clinical attention remains concentrated on (1) labeling and access in depression and related psychiatric indications, (2) safety management because MAOIs require dietary and drug interaction controls, and (3) new delivery or next-generation MAOI strategies competing for the same patient need.

The market position of Parnate is shaped less by blockbuster “new entrants” and more by:

• End-market access (formulary placement, prescribing comfort, REMS-like operational burden due to MAOI interactions).
• Comparative adoption vs. reversible MAOIs and other depression therapies.
• Supply continuity and generic penetration in major markets.

What is the current clinical-trials picture for Parnate?

No actionable, time-stamped “live” Parnate-specific trial dataset is provided in the input. Under the operating constraint that prevents producing incomplete or inaccurate trial statements, this report includes only high-confidence, non-fabricated clinical-trials implications rather than naming trial identifiers, start dates, endpoints, or status.

Clinical implication for R&D and strategy (what to underwrite):

• Efficacy re-appraisal is likely to be modest relative to newer antidepressants because Parnate is established and already has known clinical performance and safety considerations.
• The highest value clinical work is typically operational: interaction mitigation, patient selection, real-world tolerability, and protocols that reduce prescriber friction.

How does Parnate compete in the antidepressant market?

Parnate competes in a crowded antidepressant landscape where differentiation comes from the MAOI class effect and clinical niche, not broad first-line use.

Key market-structure drivers:

1. Prescriber adoption barriers
   MAOIs require strict dietary and drug interaction management. This limits prescribing unless supported by strong patient education workflows and clinician familiarity.
2. Formulary dynamics
   Modern managed care and payers favor agents with lower operational burden. Parnate’s access depends on formulary exceptions, prior authorization policies, and clinician experience.
3. Patient segmentation
   Parnate is most likely to be used for patients with treatment-resistant depression or where other options fail, but usage patterns depend on local guidelines and care pathways.

What does market analysis show for Parnate demand?

With no provided proprietary sales data, this analysis frames market demand using class-typical patterns and constraint-based valuation drivers rather than inventing numbers.

Commercial demand characteristics for Parnate-type MAOI therapy:

• Lower utilization volume vs. first-line classes (SSRIs/SNRIs) due to operational burden.
• Higher per-prescriber “commitment” once adopted because clinicians who use MAOIs often develop workflow familiarity.
• Generic substitution impact
  The existence and penetration level of generic tranylcypromine in the relevant geography will typically compress brand share, leaving brand Parnate demand to patients captured via formulary placement and prescriber behavior.

2025-2035 market projection: base case, bull case, bear case

Because no input includes geography, pricing, current revenue, unit volume, payer mix, or trial-level milestones, the projection below is structured as directional scenario ranges tied to measurable levers. It avoids fabricated base-year sales figures.

Projection logic (what moves the curve)

• Access and formulary placement (primary driver)
  Better formulary access expands eligible patient pool and increases treatment starts.
• Safety operations and adherence support (secondary driver)
  Stronger patient management programs reduce discontinuations from interaction fear and side effects.
• Generic and competitive pressure (counterweight)
  Increased generic penetration or stronger competitors in treatment-resistant depression reduces net revenue per patient and share.

Scenario table (directional, investment-grade framing)

Timeframe	Bear case (headwinds)	Base case (status-managed growth)	Bull case (access expansion)
2025-2027	Flat to declining net demand as formulary barriers persist; payer friction blocks switches	Moderate stabilization with limited share gains as niche workflows expand	Measurable formulary gains in selected plans; higher treatment starts in TRD pathways
2028-2031	Continued erosion from competitive alternatives and prescribing inertia	Slow growth supported by continued niche prescribing and supply continuity	Broader adoption as clinician protocols standardize and safety operations improve
2032-2035	Declining brand share under pressure from pricing and alternatives	Low-to-mid single-digit net demand growth driven by consistent access	Higher single-digit net growth where MAOI pathways become embedded in TRD care

Investment interpretation:

• Most upside is access-driven, not efficacy-driven.
• Most downside is operational (interaction management, prescriber reluctance) and pricing pressure (generic competition).

What does this mean for a development strategy around Parnate?

If the objective is to improve commercial durability or defend niche share, the most credible development angles are those that reduce adoption friction and increase patient continuity, not those that merely replicate known antidepressant efficacy.

Development priorities that typically map to measurable payer and prescriber outcomes:

• Patient selection and risk stratification (who benefits with manageable interaction burden).
• Interaction mitigation toolkits (structured guidance, prescriber workflows, patient education).
• Real-world tolerability endpoints (discontinuation rates, dietary adherence support, hospitalization avoidance).

Key Takeaways

• Parnate’s clinical value is established, and the main commercial lever is access rather than a repeat efficacy story.
• Operational burden around MAOI interactions limits broad adoption and shapes formulary outcomes.
• Without verified trial-level inputs, the clinically actionable takeaway is that future value creation for Parnate-like assets depends on protocolization, safety management, and patient continuity.
• 2025-2035 outcomes are scenario-dependent: upside is most likely tied to expanded coverage and standardized prescribing workflows; downside is most likely tied to persistent payer friction and pricing pressure.

FAQs

1. Is Parnate used for treatment-resistant depression?
   Yes, MAOI therapies including tranylcypromine are used in subsets of treatment-resistant depression where clinicians pursue options beyond first-line antidepressants, subject to local guideline and coverage pathways.

2. What limits Parnate adoption in mainstream prescribing?
   MAOI dietary and drug interaction management requirements increase operational complexity for prescribers and patients.

3. How does generic competition typically affect Parnate’s market?
   Generic penetration generally compresses brand revenue per prescription and shifts demand toward whichever product is cheapest or most formulary-preferred.

4. What type of clinical evidence is most likely to move payer decisions for Parnate?
   Evidence that reduces discontinuations and improves adherence through structured safety and interaction management protocols.

5. What is the most likely driver of market growth from 2025-2035?
   Formulary access and standardized real-world prescribing workflows in appropriate patient pathways.

---

References

[1] APA. Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR). American Psychiatric Association.
[2] FDA. Drug Safety Communications and labeling resources for monoamine oxidase inhibitors (MAOIs). U.S. Food and Drug Administration.
[3] Clinical guideline sources on treatment-resistant depression and antidepressant selection pathways (various publishers).